A number of research firms have changed their ratings and price targets for Zimmer Biomet (NYSE: ZBH):

  • 1/25/2019 – Zimmer Biomet was given a new $135.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 1/22/2019 – Zimmer Biomet had its price target lowered by analysts at Stifel Nicolaus from $150.00 to $135.00. They now have a “buy” rating on the stock.
  • 1/18/2019 – Zimmer Biomet was given a new $135.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 1/15/2019 – Zimmer Biomet had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 1/12/2019 – Zimmer Biomet was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Over the past three months, Zimmer Biomet has underperformed its industry. We are concerned about the company's escalating costs and expenses that are exerting considerable pressure on the bottom line. Also, declining dental sales at CER is a drag. Adverse currency movements continue to remain a major headwind for the company. However, post a mixed third quarter by Zimmer Biomet, we are hopeful about the company’s consistent efforts in product and renovation through research and development. Improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its focus on priority areas like quality remediation, supply recovery efforts and product launches, Zimmer Biomet reported strong top-line numbers within its S.E.T arm.”
  • 1/6/2019 – Zimmer Biomet was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Over the past three months, Zimmer Biomet has underperformed its industry. We are concerned about the company's escalating costs and expenses that are exerting considerable pressure on the bottom line. Also, declining dental sales at CER is a drag. Adverse currency movements continue to remain a major headwind for the company. However, post a mixed third quarter by Zimmer Biomet, we are hopeful about the company’s consistent efforts in product and renovation through research and development. Improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its focus on priority areas like quality remediation, supply recovery efforts and product launches, Zimmer Biomet reported strong top-line numbers within its S.E.T arm.”
  • 1/2/2019 – Zimmer Biomet had its price target lowered by analysts at Morgan Stanley from $149.00 to $126.00. They now have an “overweight” rating on the stock.
  • 1/2/2019 – Zimmer Biomet is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $108.00 price target on the stock.
  • 1/2/2019 – Zimmer Biomet was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating. They now have a $127.00 price target on the stock, up previously from $122.00.
  • 12/19/2018 – Zimmer Biomet was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $118.00 price target on the stock, down previously from $140.00.
  • 12/17/2018 – Zimmer Biomet is now covered by analysts at Credit Suisse Group AG. They set an “underperform” rating and a $102.00 price target on the stock.
  • 12/6/2018 – Zimmer Biomet was given a new $135.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Shares of Zimmer Biomet stock opened at $105.84 on Tuesday. The firm has a market capitalization of $21.91 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 2.11 and a beta of 1.16. The company has a quick ratio of 0.96, a current ratio of 1.89 and a debt-to-equity ratio of 0.70. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $134.55.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Friday, October 26th. The medical equipment provider reported $1.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.03. The business had revenue of $1.84 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. Zimmer Biomet’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.72 earnings per share. As a group, analysts predict that Zimmer Biomet Holdings Inc will post 7.64 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 31st. Stockholders of record on Friday, December 28th will be given a $0.24 dividend. The ex-dividend date is Thursday, December 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 11.96%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Town & Country Bank & Trust CO dba First Bankers Trust CO boosted its position in Zimmer Biomet by 100.0% during the fourth quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 3,306 shares of the medical equipment provider’s stock valued at $343,000 after purchasing an additional 1,653 shares during the last quarter. Calamos Advisors LLC boosted its position in Zimmer Biomet by 6.8% during the third quarter. Calamos Advisors LLC now owns 36,675 shares of the medical equipment provider’s stock valued at $4,822,000 after purchasing an additional 2,322 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Zimmer Biomet by 9.8% during the third quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock valued at $1,524,453,000 after purchasing an additional 1,033,717 shares during the last quarter. AXA boosted its position in Zimmer Biomet by 2.0% during the third quarter. AXA now owns 112,525 shares of the medical equipment provider’s stock valued at $14,793,000 after purchasing an additional 2,166 shares during the last quarter. Finally, Palladium Partners LLC acquired a new stake in Zimmer Biomet during the third quarter valued at $254,000. 87.98% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.